DMAA
Drugs Made In America Acquisition
$10.87
$0.00 (0%)Oct 28, 2026
Key metrics
The numbers that frame DMAA today
- Market cap
- $263.89M
- P/E (TTM)
- 57.2
- ROIC
- 2.8%
- Div yield
- 0%
- 52wk Low
- $10.30
- 52wk High
- $10.89
Growth
Revenue and earnings trend for DMAA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about DMAA
Is Drugs Made In America Acquisition a good buy?
Hold. Drugs Made In America Acquisition has mixed quality and strong momentum. The setup is mixed. Growth looks weak. That could put pressure on the long-term business case. We think Drugs Made In America Acquisition is selling at a fair price.
What is the market capitalization of DMAA?
Drugs Made In America Acquisition's market capitalization is $263.89M.
What is the P/E (TTM) ratio for DMAA stock?
Drugs Made In America Acquisition's P/E (TTM) ratio is 57.2, based on trailing earnings.
What is the 52-week high for DMAA stock?
The 52-week high for Drugs Made In America Acquisition is $10.89. The current close of $10.87 is 0.2% below that high.
What is the 52-week low for DMAA stock?
The 52-week low for Drugs Made In America Acquisition is $10.30. The current close of $10.87 is 5.5% above that low.
Does DMAA stock pay dividends?
Drugs Made In America Acquisition does not currently show a dividend per share in the company data.